St. Gallen, Switzerland:
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (Vifor) introduced right now that by choice dated October 19, 2022, SIX Exchange Regulation AG (SER) has accredited an extension of the varied exemptions from sure disclosure and publicity obligations granted by SER to Vifor Pharma AG beforehand (see Vifor Pharma AG’s advert hoc announcement of August 2, 2022).
The related elements of the choice of SER of October 19, 2022, are as follows:
“I. Die Vifor Pharma AG (Emittent) wird im Hinblick auf die geplante Dekotierung bis und mit 28. Februar 2023 von folgenden Pflichten befreit:
a. Veröffentlichung des Halbjahresberichts 2022 (Art. 49 ff. KR i.V.m. Art. 10 ff. Richtlinie Rechnungslegung [RLR] und Art. 9 Ziff. 2.01 (2) Richtlinie Regelmeldepflichten [RLRMP]);
b. Veröffentlichung von Ad hoc-Mitteilungen (Art. 53 KR i.V.m. der Richtlinie betr. Ad hoc-Publizität [RLAhP]), davon ausgenommen ist die Veröffentlichung einer Ad hoc-Mitteilung betreffend die Bekanntgabe des Zeitpunkts der Dekotierung der Namensaktien des Emittenten, sobald dieser bestimmt ist;
c. Offenlegung von Management-Transaktionen (Art. 56 KR);
d. Führung des Unternehmenskalenders (Art. 52 KR);
e. Erfüllung der nachfolgend genannten Regelmeldepflichten (Art. 55 KR i.V.m. Art. 9 der Richtlinie Regelmeldepflichten [RLRMP]):
– Ziff. 1.05 (Änderung des Revisionsorgans);
– Ziff. 1.06 (Änderung des Bilanzstichtags);
– Ziff. 1.08 (4) (Änderung Weblink zum Unternehmenskalender);
– Ziff. 1.08 (5) (Änderung Weblink zu den Jahres- und Halbjahresberichten);
– Ziff. 2.01 (Einreichung Finanzbeschlüsse);
– Ziff. 3.05 (Beschlüsse betreffend Opting Out/Opting Up);
– Ziff. 3.06 (Änderung betreffend Vinkulierungsbestimmungen);
– Ziff. 5.02 (Meldung des bedingten Kapitals).
II. Die Befreiung gemäss Ziff. I beginnt mit Veröffentlichung der Ad hoc-Mitteilung gemäss den Vorgaben in Ziff. VI.
III. Der Emittent wird bis und mit 28. Februar 2023 von den Pflichten gemäss Ziff. I befreit, sofern und soweit keiner der folgenden Tatbestände bis zum 28. Februar 2023 eintritt:
a. Eintritt eines Minderheitsaktionärs oder mehrerer Minderheitsaktionäre in das Verfahren um Kraftloserklärung der Namensaktien des Emittenten nach Art. 137 des Bundesgesetzes über die Finanzmarktinfrastrukturen und das Marktverhalten im Effekten- und Devisenhandel vom 19. Juni 2015 (Finanzmarktinfrastrukturgesetz, FinfraG) vor dem zuständigen Gericht;
b. Rückzug der Klage um Kraftloserklärung der Namensaktien des Emittenten vor dem zuständigen Gericht durch die Klägerin oder durch eine Rechtsnachfolgerin;
c. Abweisung der Klage um Kraftloserklärung der Namensaktien des Emittenten durch das zuständige Gericht;
d. Weiterzug des Urteils des zuständigen Gerichts betreffend die Kraftloserklärung der Namensaktien des Emittenten.
Sollte einer der Tatbestände gemäss dieser Ziffer III. Bst. a. bis d. bis zum 28. Februar 2023 eintreten, leben die Pflichten des Emittenten gemäss Ziff. I umgehend wieder auf.
Im Falle eines Wiederauflebens der Pflichten gemäss Ziff. I, hat der Emittent den Halbjahresbericht 2022 innert sechs Wochen ab dem Tag des jeweiligen Wiederauflebens der Pflichten gemäss Ziff. I zu publizieren und SIX Exchange Regulation AG einzureichen (Art. 50 KR i.V.m. Art. 11 ff. RLR und Art. 9 Ziff. 2.01 (2) RLRMP).”
Unofficial English translation:
“I. In view of the envisaged delisting, Vifor Pharma AG (Issuer) is hereby exempted from the next obligations till and together with 28 February 2023:
a. Publication of the Half-Year Report 2022 (artwork. 49 et. seq. LR together with artwork. 10 et seq. Directive on Financial Reporting [DFR] and artwork. 9 no. 2.01 (2) Directive Regular Reporting Obligations [DRRO]);
b. Publication of advert hoc notices (artwork. 53 LR together with the Directive on Ad Hoc Publicity [DAH]), with the exception of the publication of an advert hoc discover regarding the announcement of the date of delisting of the Issuer’s registered shares as quickly as such date has been decided;
c. Disclosure of administration transactions (artwork. 56 LR);
d. Keeping of the company calendar (artwork. 52 LR);
e. Fulfillment of the next common reporting obligations (artwork. 55 LR together with artwork. 9 DRRO):
– no. 1.05 (change of exterior auditors);
– no. 1.06 (change of stability sheet date);
– no. 1.08 (4) (change of weblink to the company calendar);
– no. 1.08 (5) (change of weblink to the annual and half-year reviews);
– no. 2.01 (submitting of annual reviews);
– no. 3.05 (resolutions relating to opting out/ opting up);
– no. 3.06 (modifications relating to restrictions on transferability of shares);
– no. 5.02 (reporting of conditional capital).
II. The exemptions pursuant to Section I shall be efficient following the publication of the advert hoc discover pursuant to, and in accordance with the necessities of, Section VI.
III. The Issuer shall be exempted from the obligations pursuant to Section I till and together with 28 February 2023, if none of the next occasions happens by 28 February 2023:
a. Joinder of a minority shareholder or a number of minority shareholders to the proceedings for cancellation of the Issuer’s registered shares pursuant to artwork. 137 of the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading of 19 June 2015 (Financial Market Infrastructures Act, FMIA) earlier than the competent courtroom;
b. Withdrawal of the motion for cancellation of the Issuer’s registered shares earlier than the competent courtroom by the plaintiff or by a authorized successor;
c. Dismissal of the motion for cancellation of the Issuer’s registered shares by the competent courtroom;
d. The judgment of the competent courtroom relating to the cancellation of the Issuer’s registered shares is being appealed.
Should any of the occasions pursuant to this Section III. letter a. to d. happen till 28 February 2023, the Issuer’s obligations pursuant to Section I shall revive instantly.
In the occasion of a revival of the obligations pursuant to Section I, the Issuer should publish and undergo SIX Exchange Regulation AG the Half-Year Report 2022 inside six weeks from the date of the respective revival of the obligations pursuant to Section I (artwork. 50 LR together with artwork. 11 et seq. DFR and artwork. 9 no. 2.01 (2) DRRO).”
About CSL Vifor
CSL Vifor is a worldwide associate of alternative for prescription drugs and progressive, main therapies in iron deficiency, dialysis and nephrology & uncommon illness. We specialise in strategic world partnering, in-licensing and creating, manufacturing and advertising and marketing pharmaceutical merchandise for precision healthcare, aiming to assist sufferers world wide lead higher, more healthy lives. Headquartered in St. Gallen, Switzerland, CSL Vifor additionally contains the joint firm Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The guardian firm, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 folks and delivers its lifesaving therapies to folks in additional than 100 international locations. For extra details about CSL Vifor go to, www.cslvifor.com.
Forward-Looking Statements
This announcement might include statements that represent forward-looking statements. The phrases “anticipate”, “believe”, “expect”, “estimate”, “aim”, “project”, “forecast”, “estimate”, “risk”, “likely”, “intend”, “outlook”, “should”, “could”, “would”, “may”, “will”, “continue”, “plan”, “probability”, “indicative”, “seek”, “target”, “plan” and different comparable expressions are supposed to establish forward-looking statements.
Any such statements, opinions and estimates on this announcement converse solely as of the date hereof and are based mostly on assumptions and contingencies topic to vary with out discover, as are statements about market and trade developments, projections, steerage and estimates. Forward-looking statements are offered as a common information solely. The forward-looking statements on this announcement will not be indications, ensures or predictions of future efficiency and contain identified and unknown dangers, uncertainties and different elements, many of that are past the management of CSL and Vifor and their officers, workers, brokers and advisors, and might contain vital components of subjective judgement and assumptions as to future occasions which can or will not be appropriate, and might trigger precise outcomes to vary materially from these expressed or implied in such statements. You are strongly cautioned to not place undue reliance on forward-looking statements.
This announcement shouldn’t be a monetary product or funding recommendation, a advice to amass or promote securities or accounting, authorized or tax recommendation. It doesn’t represent an invite or provide to use for securities. It has been ready with out considering the aims, monetary or tax scenario or wants of people. Before investing choice, potential buyers ought to think about the appropriateness of the data having regard to their very own aims, monetary and tax scenario and wants and search authorized and taxation recommendation acceptable for his or her jurisdiction. CSL and Vifor will not be licensed to supply monetary product recommendation in respect of an funding in securities.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20221019006063/en/
